Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Recruiting

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab - CA013-004

Updated: 30 May, 2018   |   ClinicalTrials.gov

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the trial guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.
Print this page CA013-004
Download Guide

SELECT LANGUAGE

Trial Details

  • Phase 1/Phase 2

    Phase

  • Gender(s)

  • 18+

    Age Range

  • 12

    Location(s)

  • Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Cohort Expansion Combination Therapy (Dose Expansion)
Biological: BMS-986179 Drug: rHuPH20 Biological: Nivolumab
Experimental: Combination Therapy (Pharmacodynamic Sub-study)
Drug: rHuPH20 Biological: BMS-986179 Biological: Nivolumab
Experimental: Combination Therapy with Monotherapy Lead-In (Dose-Escalation)
Drug: rHuPH20 Biological: BMS-986179 Biological: Nivolumab
Experimental: Monotherapy (Dose Expansion)
Biological: BMS-986179 Drug: rHuPH20

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Men and women at least 18 years of age - Advanced solid tumors - Eastern Cooperative Oncology Group (ECOG) 0-1 - Acceptable lab testing results - Allow biopsies Exclusion Criteria: - Central nervous system (CNS) tumors - Uncontrolled or significant cardiovascular diseases - Active or known autoimmune disease - Organ transplant Other protocol defined inclusion/exclusion criteria could apply

Have questions? Call 855-907-3286 or Email Us

Have questions?
Call 855-907-3286 or Email Us